Patent: 9,993,529
✉ Email this page to a colleague
Summary for Patent: 9,993,529
Title: | Stable formulations of a hyaluronan-degrading enzyme |
Abstract: | Provided are compositions that are stable formulations of a hyaluronan-degrading enzyme or are stable co-formulations of a fast-acting insulin and a hyaluronan degrading enzyme, including a recombinant human PH20 (rHuPH20). |
Inventor(s): | Yang; Tzung-Horng (Del Mar, CA), Vaughn; Daniel Edward (Encinitas, CA), Labarre; Michael James (San Diego, CA), Caster; Christopher L. (Del Mar, CA), Nicol; Francois (Carlsbad, CA), Kim; Donghyun (San Diego, CA) |
Assignee: | Halozyme, Inc. (San Diego, CA) |
Application Number: | 13/507,262 |
Patent Claims: | see list of patent claims |
Details for Patent 9,993,529
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 06/14/1996 | ⤷ Try a Trial | 2028-04-28 |
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 08/06/1998 | ⤷ Try a Trial | 2028-04-28 |
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 09/06/2007 | ⤷ Try a Trial | 2028-04-28 |
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 06/06/2017 | ⤷ Try a Trial | 2028-04-28 |
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 11/15/2019 | ⤷ Try a Trial | 2028-04-28 |
Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | 06/07/2000 | ⤷ Try a Trial | 2028-04-28 |
Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | 01/19/2001 | ⤷ Try a Trial | 2028-04-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |